CAH trades 23.0% below Wall Street's consensus target of $273.22.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CAH achieves its forward estimates and maintains a stable P/E multiple of 17.7x. This scenario reflects the blended consensus of 33 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 23, 2026, Cardinal Health, Inc. (CAH) has a Wall Street consensus price target of $273.22, based on estimates from 33 covering analysts. With the stock currently trading at $222.04, this represents a potential upside of +23.0%. The company has a market capitalization of $52.00B.
Analyst price targets range from a low of $250.00 to a high of $292.00, representing a 15% spread in expectations. The median target of $275.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 18 analysts rating the stock as a Buy or Strong Buy,15 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, CAH trades at a trailing P/E of 30.7x and forward P/E of 17.7x. Analysts expect EPS to grow +73.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $282.04, with bear and bull scenarios of $177.69 and $371.62 respectively. Model confidence stands at 49/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MCKMcKesson Corporation | $106.2B | $891.23 | $953.00 | +6.9% | Buy | 20.0x | 31 |
 HSICHenry Schein, Inc. | $10.0B | $87.43 | $92.33 | +5.6% | Buy | 16.2x | 34 |
 OMIOwens & Minor, Inc. | $171M | $2.24 | $15.60 | +596.4% | Hold | 2.3x | 10 |
 NXSTNexstar Media Group, Inc. | $5.1B | $167.53 | $240.00 | +43.3% | Buy | 5.4x | 24 |
 JNJJohnson & Johnson | $648.0B | $269.19 | $286.93 | +6.6% | Buy | 23.4x | 40 |
 PFEPfizer Inc. | $159.2B | $27.93 | $28.50 | +2.0% | Hold | 9.4x | 39 |
 ABTAbbott Laboratories | $180.7B | $103.73 | $121.50 | +17.1% | Buy | 18.8x | 41 |
 BDXBecton, Dickinson and Company | $50.4B | $183.00 | $186.88 | +2.1% | Hold | 14.4x | 34 |
 CVSCVS Health Corp. | $111.1B | $87.10 | $111.20 | +27.7% | Buy | 10.9x | 41 |
 HCAHCA Healthcare, Inc. | $94.9B | $438.12 | $455.19 | +3.9% | Buy | 14.9x | 46 |
Quick answers to the most common questions about buying CAH stock.
The consensus Wall Street price target for CAH is $273.22, representing 23.0% upside from the current price of $222.04. With 33 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CAH has a consensus rating of "Buy" based on 33 Wall Street analysts. The rating breakdown is predominantly bullish, with 18 Buy/Strong Buy ratings. The consensus 12-month price target of $273.22 implies 23.0% upside from current levels.
With a forward P/E of 17.7005x, CAH trades at a relatively low valuation. The consensus target of $273.22 implies 23.0% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $292 for CAH, while the most conservative target is $250. The consensus of $273.22 represents the median expectation. Our quantitative valuation model projects a bull case target of $372 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CAH is heavily covered by Wall Street, with 33 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 18 have Buy ratings, 15 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CAH stock forecast based on 33 Wall Street analysts shows a consensus price target of $273.22, with estimates ranging from $250 (bear case) to $292 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $282, with bear/bull scenarios of $178/$372.
Our quantitative valuation model calculates CAH's fair value at $282 (base case), with a bear case of $178 and bull case of $372. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 49/100.
CAH trades at a forward P/E ratio of 17.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 30.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on CAH, with a "Buy" consensus rating and $273.22 price target (23.0% upside). 18 of 33 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CAH analyst price targets range from $250 to $292, a 15% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $273.22 consensus represents the middle ground. Our model's $178-$372 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.